{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Subjects who complete the Week 72 Visit will be contacted 6 and 12 months later via phone or', 'email by research staff to enquire if any treatment for TED has been received since last study', 'contact. If yes, subject will be questioned regarding type of treatment and outcome/response.', 'An overview of the study design is presented in Figure 9.1, and details of study activities were', 'previously presented in Section 2.1, Schedule of Assessments.', 'Figure 9.1', 'Schematic of Study Design', 'Double-Masked Treatment Period', 'Screen Baseline', 'Teprotumumab or Placebo 1,2', 'Follow-Up Period', 'Follow-Up', 'Contact5', '48 Weeks 3,4', '24 Weeks', '48 Weeks', 'Clinic Visits', '<', 'Clinic Visits', '>', '*', '2 6', 'Day 16iW36W46', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W28', 'W36', 'W48', 'W60', 'W72', 'W96', 'W120', 'weeks', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M24', 'M30', 'predose', 'Randomization <', 'Study Week/Month', '>', 'n=38/group\u00b9', '*', 'Infusion of study drug.', '1.', 'Subjects will be randomized in a 1:1 ratio (stratified by tobacco use status) to receive:', 'a. Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions);', 'or', 'b. Placebo (placebo q3W for all 8 infusions).', '2. Visit windows are 1 day for Weeks 1 and 4, 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24.', '3. Subjects who are proptosis responders or non-responders who do not elect to participate in the open-label extension study will enter a 48-week', 'Follow-Up Period. Subjects who are responders at Week 24 but relapse during the Follow-Up Period may enter the open-label study and receive', '8 infusions if they meet the criteria defined in Section 9.3.4.', '4.', 'Visit windows of 7 days.', '5. Subjects who complete the Week 72 Visit will be contacted via phone or email by research staff to enquire if any treatment for TED has been', 'received since last study contact.', '6.', 'Subjects will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments; phone/email', 'contacts will also occur the day after any clinic visit where a subject experiences an infusion-related AE.', '7.', 'Subjects who are proptosis non-responders at Week 24 of the double-masked Treatment Period will be offered the option to enter an open-label', 'extension study and receive 8 infusions of teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg for the remaining 7 infusions).', '9.2', 'Discussion of Study Design', 'This study is a randomized, double-masked, placebo-controlled, parallel-group, multi-center', 'study designed according to standard principles for adequate and well-controlled studies. The', 'study population is well-defined and is consistent with the expected target population for whom', \"teprotumumab will be indicated (adult subjects with Graves' disease and moderate-to-severe\", 'active TED).', 'The measurements used in this study for the primary and secondary endpoints (proptosis, CAS,', 'and GO-QoL questionnaire) are established and well-validated endpoints that have been shown', 'to correlate significantly with TED.', 'The sample size for this study was based on the data from the TED01RV study. A sample size of', '38 subjects per group provides 90% power at the 2-sided alpha 0.05 level to detect a difference', 'of 39% between teprotumumab and placebo in the proptosis responder rate; this sample size has', 'been adjusted for a 16% dropout rate.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 65 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Given the teratogenic effects of teprotumumab noted in a monkey embryo-fetal development', 'toxicity study (see Section 7.1.3.2 for details) and pharmacokinetic profile of teprotumumab (see', 'Section 7.1.3.4.3), all subjects (men and women) are required to use adequate contraception and', 'report any pregnancies for at least 6 months after the last dose of study drug. Six months after the', 'last dose, the estimated plasma concentration (0.2 g/mL) is considered reasonably safe with a', 'low risk of teratogenicity. Furthermore, a 6-month waiting period is in line with', 'recommendations given for other teratogens, such as cytostatic chemotherapy.', '9.3', 'Selection of Study Population', '9.3.1 Inclusion Criteria', 'Eligible subjects must meet all of the following criteria:', '1. Written informed consent.', '2. Male or female subject between the ages of 18 and 80 years, inclusive, at Screening.', \"3. Clinical diagnosis of Graves' disease associated with active TED with a CAS > 4 (on the\", '7-item scale) for the most severely affected eye at Screening and Baseline.', '4. Moderate-to-severe active TED (not sight-threatening but has an appreciable impact on', 'daily life), usually associated with one or more of the following: lid retraction > 2 mm,', 'moderate or severe soft tissue involvement, exophthalmos > 3 mm above normal for race', 'and gender, and/or inconstant or constant diplopia.', '5. Onset of active TED symptoms (as determined by subject records) within 9 months prior', 'to Baseline.', '6. Subjects must be euthyroid with the baseline disease under control or have mild hypo- or', 'hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3] levels', '< 50% above or below the normal limits) at Screening. Every effort should be made to', 'correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state', 'for the full duration of the clinical trial.', '7. Does not require immediate surgical ophthalmological intervention and is not planning', 'corrective surgery/irradiation during the course of the study.', '8. Alanine aminotransferase (ALT) or AST <3 times the upper limit of normal (ULN) or', 'serum creatinine <1.5 times the ULN according to age at Screening.', '9. Diabetic subjects must have well-controlled stable disease (defined as HbAlc < 9.0%', 'with no new diabetic medication [oral or insulin) or more than a 10% change in the dose', 'of a currently prescribed diabetic medication within 60 days prior to Screening).', '10. Women of childbearing potential (including those with an onset of menopause <2 years', 'prior to Screening, non-therapy-induced amenorrhea for <12 months prior to Screening,', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 66 of 117']\n\n###\n\n", "completion": "END"}